Biocon Q2 FY27: revenue up 2.2% to ₹4,389 Cr, net profit down 57.3% to ₹57 Cr
Results · Finvezto · 4 Nov 2026 · Biocon (BIOCON)
Results Q2 FY27, ₹ Cr
| Q2 FY27 | ₹ Cr | QoQ | YoY |
|---|---|---|---|
| Revenue | 4,389 | +1.2% | +2.2% |
| Operating profit | 831 | -1.9% | -0.5% |
| Net profit | 57 | -58.6% | -57.3% |
| Operating margin | 18.9% | -0.6 pp | -0.5 pp |
| Net margin | 1.3% | -1.9 pp | -1.8 pp |
Key points
- Biocon Limited reported consolidated revenue from operations of Rs 4,389 crore for Q2 FY27, up 2% year-on-year, while EBITDA declined 7% to Rs 865 crore and reported net profit fell 52% to Rs 41 crore. NSE filing
- Biopharma revenue increased 5% year-on-year to Rs 3,583 crore, driven by a 10% rise in generics to Rs 774 crore and a 3% growth in biosimilars to Rs 2,809 crore. NSE filing
- Revenue was ₹4,389 Cr, up 2.2% on a year earlier and up 1.2% on the quarter before. Finvezto data
What to watch
- Operating margin over the last 4 quarters (Dec 25, Mar 26, Jun 26, Sep 26): 20.0%, 22.6%, 19.5%, 18.9%.
- Net profit over the last 4 quarters (Dec 25, Mar 26, Jun 26, Sep 26), ₹ Cr: -52, 199, 137, 57.
Links
NSE filing (PDF) · Company page · Results tracker
Anand Ganapathy K | SEBI Registered Research Analyst | INH000016630.